Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda R Moore

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Cancer Cell|August 10, 2021
The promise and peril of KRAS G12C inhibitorsAmanda R Moore, Shiva Malek
Nature Reviews. Drug Discovery|June 13, 2020
RAS-targeted therapies: is the undruggable drugged?Amanda R Moore, Scott C Rosenberg, Frank McCormick, et al.
Nature Reviews. Drug Discovery|May 15, 2021
RAS-targeted therapiesAmanda R Moore, Scott C Rosenberg, Frank McCormick, et al.
Nature Reviews. Drug Discovery|October 21, 2020
Author Correction: RAS-targeted therapies: is the undruggable drugged?Amanda R Moore, Scott C Rosenberg, Frank McCormick, et al.
The Journal of Biological Chemistry|December 8, 2020
Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signalingEmilie Ceraudo, Mizuho Horioka, Jordan M Mattheisen, et al.
Plos One|August 19, 2016
A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and ColonDong Gao, Yu Zhan, Wei Di, et al.
Nature Cancer|May 7, 2026
A high-MAPK, low-WNT cell state drives metastatic dissemination in colorectal cancerMelanie Heinlein, Ginny X Li, Noelyn Kljavin, et al.
Cell Reports|October 14, 2020
GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal MelanomaAmanda R Moore, Leili Ran, Youxin Guan, et al.
Cell Reports|March 1, 2018
GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal MelanomaAmanda R Moore, Leili Ran, Youxin Guan, et al.
Nature Genetics|April 19, 2016
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanomaAmanda R Moore, Emilie Ceraudo, Jessica J Sher, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Cancer Cell|August 10, 2021
The promise and peril of KRAS G12C inhibitorsAmanda R Moore, Shiva Malek
Nature Reviews. Drug Discovery|June 13, 2020
RAS-targeted therapies: is the undruggable drugged?Amanda R Moore, Scott C Rosenberg, Frank McCormick, et al.
Nature Reviews. Drug Discovery|May 15, 2021
RAS-targeted therapiesAmanda R Moore, Scott C Rosenberg, Frank McCormick, et al.
Nature Reviews. Drug Discovery|October 21, 2020
Author Correction: RAS-targeted therapies: is the undruggable drugged?Amanda R Moore, Scott C Rosenberg, Frank McCormick, et al.
The Journal of Biological Chemistry|December 8, 2020
Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signalingEmilie Ceraudo, Mizuho Horioka, Jordan M Mattheisen, et al.
Plos One|August 19, 2016
A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and ColonDong Gao, Yu Zhan, Wei Di, et al.
Nature Cancer|May 7, 2026
A high-MAPK, low-WNT cell state drives metastatic dissemination in colorectal cancerMelanie Heinlein, Ginny X Li, Noelyn Kljavin, et al.
Cell Reports|October 14, 2020
GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal MelanomaAmanda R Moore, Leili Ran, Youxin Guan, et al.
Cell Reports|March 1, 2018
GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal MelanomaAmanda R Moore, Leili Ran, Youxin Guan, et al.
Nature Genetics|April 19, 2016
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanomaAmanda R Moore, Emilie Ceraudo, Jessica J Sher, et al.
Pageof 2